Medication
Ipravent
DIN 02246084 · Aa Pharma Inc
What it is
- Active ingredients
- Ipratropium Bromide — 42 mcg
- Form and route
- Solution · Nasal
- Schedule
- PRESCRIPTION
- Authorised since
- 2002-12-03
Source: Health Canada — Drug Product Database. Data current as of 2026-08-12.
Products with the same active ingredient
No other medication authorised in Canada shares this active ingredient.
Health Canada groups products by their active ingredients. No other marketed product shares this one’s group, which usually means it is still the only authorised version — not that alternatives were hidden or missed.
Ontario Drug Benefit coverage
As of 31 July 2026Off-formulary interchangeable Part III-B
Ontario has designated this product interchangeable with a brand product, but it is not an ODB benefit — Part III-B, Off-Formulary Interchangeable. Ontario does not pay for it under the benefit list.
Source: Ontario Ministry of Health — ODB Formulary. Data current as of 2026-07-28. Ontario only. Formulary edition 4342, effective 31 July 2026.
How it is classified
- Anatomical main group
- Respiratory system
- ATC code
- R01AX03
The Anatomical Therapeutic Chemical code records the body system a medicine acts on and its chemical grouping. It is not a statement of what this medication treats, and nothing on this page is. For the full classification of R01AX03, see the WHO ATC/DDD Index.
Recalls and safety alerts
Recall matching is not available yet.
RxMonitor does not yet match Health Canada recalls to individual products — that arrives in a later release. Nothing on this page should be read as confirming that this medication has not been recalled.